Cargando…
Nanomicelles for GLUT1-targeting hepatocellular carcinoma therapy based on NADPH depletion
Hepatocellular carcinoma (HCC) is a malignant tumor leading cancer-associated high mortality worldwide. Unfortunately, the most commonly used drug therapeutics not only lack of target ability and efficiency, but also exhibit severe systemic toxicity to normal tissues. Thus, effective and targeted na...
Autores principales: | Zhang, Congyi, Liu, Zehui, Wang, Feng, Zhang, Bin, Zhang, Xirui, Guo, Peiwen, Li, Tianwei, Tai, Sheng, Zhang, Changmei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809347/ https://www.ncbi.nlm.nih.gov/pubmed/36579634 http://dx.doi.org/10.1080/10717544.2022.2162160 |
Ejemplares similares
-
Targeting uridine–cytidine kinase 2 induced cell cycle arrest through dual mechanism and could improve the immune response of hepatocellular carcinoma
por: Wu, Dehai, et al.
Publicado: (2022) -
BTF3 promotes proliferation and glycolysis in hepatocellular carcinoma by regulating GLUT1
por: Wang, Peng, et al.
Publicado: (2023) -
Aptamer-based self-assembled nanomicelle enables efficient and targeted drug delivery
por: Chen, Ganghui, et al.
Publicado: (2023) -
Recent development of polymer nanomicelles in the treatment of eye diseases
por: Cai, Ruijun, et al.
Publicado: (2023) -
GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma
por: Sun, Hong-Wei, et al.
Publicado: (2016)